Plethico Pharmaceuticals Ltd

Plethico Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Plethico Pharmaceuticals Ltd

₹ 7.94 -4.91%
13 Jun 2016
plethico.com BSE: 532739 NSE: PLETHICO
About

Plethico Pharmaceuticals Ltd is an India-based healthcare pharmaceutical company engaged in the manufacture and marketing of pharmaceutical and allied healthcare.

[ add key points ]
Website BSE NSE
  • Market Cap ₹ 30.8 Cr.
  • Current Price ₹ 7.94
  • High / Low ₹ /
  • Stock P/E 0.67
  • Book Value ₹ 76.0
  • Dividend Yield 0.00 %
  • ROCE 4.48 %
  • ROE -1.61 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Stock is trading at 0.10 times its book value

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 2.39% over past five years.
  • Company has a low return on equity of -1.31% over last 3 years.
  • Contingent liabilities of Rs.152 Cr.
  • Company has high debtors of 481 days.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Jun 2013 Sep 2013 Dec 2013 Mar 2014 Jun 2014 Sep 2014 Dec 2014 Mar 2015
171 146 113 76 62 53 50 21 13
153 129 95 73 57 50 46 20 17
Operating Profit 18 17 18 3 5 3 5 1 -3
OPM % 11% 11% 16% 4% 9% 6% 9% 5% -26%
-2 5 0 -0 0 -0 0 0 -320
Interest 12 14 14 11 12 11 10 12 22
Depreciation 2 2 2 2 2 2 2 2 7
Profit before tax 2 5 2 -10 -8 -11 -7 -12 -351
Tax % 0% 48% 34% -30% 0% 0% 0% 0% -31%
2 3 2 -7 -8 -11 -7 -12 -243
EPS in Rs 0.63 0.81 0.48 -1.99 -2.49 -3.16 -2.13 -3.63 -71.40
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Sep 2006 Dec 2007 15m Dec 2008 Dec 2009 Dec 2010 Dec 2011 Dec 2012 Mar 2014 15m TTM
319 549 472 471 443 412 475 531 137
229 410 381 354 333 370 517 492 131
Operating Profit 90 140 91 117 110 42 -42 40 5
OPM % 28% 25% 19% 25% 25% 10% -9% 7% 4%
10 38 -2 29 10 20 99 41 -320
Interest 6 10 18 32 35 81 56 78 54
Depreciation 5 7 7 6 7 8 8 10 13
Profit before tax 88 161 64 107 78 -27 -7 -8 -382
Tax % 2% 2% 4% 0% 25% 37% 12% 5%
86 158 61 107 58 -38 -8 -9 -274
EPS in Rs 25.25 46.48 17.86 31.42 17.00 -11.05 -2.32 -2.56 -80.32
Dividend Payout % 10% 5% 14% 8% 15% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 2%
3 Years: 6%
TTM: -66%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 477%
Stock Price CAGR
10 Years: -14%
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 4%
3 Years: -1%
Last Year: -2%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Sep 2006 Dec 2007 Dec 2008 Dec 2009 Dec 2010 Dec 2011 Dec 2012 Mar 2014
Equity Capital 34 34 34 34 34 34 34 34
Reserves 410 559 576 644 665 631 513 505
95 383 651 589 581 871 1,017 1,016
37 43 53 51 69 99 140 149
Total Liabilities 576 1,018 1,314 1,318 1,350 1,635 1,704 1,704
93 111 111 105 136 133 128 119
CWIP 24 2 19 30 3 0 0 0
Investments 138 409 719 738 776 807 807 807
321 496 465 444 435 696 769 778
Total Assets 576 1,018 1,314 1,318 1,350 1,635 1,704 1,704

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Sep 2006 Dec 2007 Dec 2008 Dec 2009 Dec 2010 Dec 2011 Dec 2012 Mar 2014
-24 70 59 150 103 -119 -37 42
-36 -255 -337 -30 -48 -31 -1 3
128 266 139 -114 -60 165 36 -57
Net Cash Flow 67 81 -138 6 -6 15 -1 -12

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Sep 2006 Dec 2007 Dec 2008 Dec 2009 Dec 2010 Dec 2011 Dec 2012 Mar 2014
Debtor Days 255 177 265 260 291 528 517 481
Inventory Days 27 17 20 27 25 32 20 14
Days Payable 22 16 28 30 23 26 21 20
Cash Conversion Cycle 260 177 257 257 292 533 517 476
Working Capital Days 248 204 316 299 302 532 486 449
ROCE % 20% 13% 10% 8% 8% 2% 4%

Shareholding Pattern

Numbers in percentages

Jun 2016
57.75%
2.70%
16.71%
22.84%
No. of Shareholders 16,430

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings